dAurAB5 is a dual PROTAC degrader targeting Aurora-A (DC50= 8.8 nM) and Aurora-B (DC50= 6.1 nM). It induces the degradation of Aurora-A and Aurora-B, leading to reduced N-Myc levels and decreased viability of IMR32 neuroblastoma cells. Additionally, dAurAB5 downregulates the levels of AAK1, PTK2, GAK, and TTK. This compound is applicable in cancer research, including neuroblastoma.
